Award
NIH Reporter #5P50CA281701-04
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
Recipient
UNIVERSITY OF TX MD ANDERSON CAN CTR
Award Amount
$329,672.00
Ceiling
$329,672.00
Awarded
September 17, 2026
Identifier
5P50CA281701-04
Award for a Phase IA trial of GRN-300, a SIK2 inhibitor, to assess its safety and efficacy in ovarian cancer, including its immunomodulatory effects and potential to enhance immune responses.
Description
This project aims to complete a Phase IA trial of GRN-300, a SIK2 inhibitor, to evaluate its safety, pharmacokinetics, pharmacodynamics, and clinical activity, and to investigate its immunomodulatory effects in ovarian cancer treatment.